NICE’s 187-page draft programme manual, published today for consultation, has more than enough by way of reform to HTA methods and processes for any market access aficionado to get their…

“Life Sciences will be one of the great drivers of growth in the twenty first century.” The first sentence of the foreword to the British Government’s new Life Sciences Vision…

The entrance of biosimilar competitors into a therapeutic area is an ever-present concern for pharmaceutical companies managing ageing product portfolios. On the other hand, any potential benefit to patients and…

The government has this week published the long-awaited draft data strategy: Data saves lives: reshaping health and social care with data. This new strategy builds upon previous attemptsto harness the NHS’s rich store of patient…

At the beginning of April, many European nations halted their vaccination programme in fears that the Oxford-AstraZeneca Covid-19 vaccine increased the recipient’s chances of developing severe and deadly blood clots.…

First in a series of articles considering the implications of NICE’s changing role for industry and patients.  NICE’s role and remit has grown and morphed over its twenty plus year…

As any experienced market access professional will tell you, securing access to a new medicine is rarely as simple as just submitting a dossier to a national body and waiting…